141 related articles for article (PubMed ID: 36879065)
1. Diagnostic effectiveness of [
Bottoni G; Fiz F; Puntoni M; Matteucci F; Monti M; DeCensi A; Nanni O; Brain E; Alberini JL; Dib B; Sacchetti G; Trimboli P; Treglia G; Harbeck N; Sola S; Gennari A; Piccardo A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2477-2485. PubMed ID: 36879065
[TBL] [Abstract][Full Text] [Related]
2. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
3. Prospective Pilot Study of
Covington MF; Hoffman JM; Morton KA; Buckway B; Boucher KM; Rosenthal RE; Porretta JM; Brownson KE; Matsen CB; Vaklavas C; Ward JH; Wei M; Buys SS; Chittoria N; Yakish ED; Archibald ZG; Burrell LD; Butterfield RI; Yap JT
AJR Am J Roentgenol; 2023 Aug; 221(2):228-239. PubMed ID: 36919879
[No Abstract] [Full Text] [Related]
4. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract][Full Text] [Related]
6.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
7. Comparison of diagnostic sensitivity of [
Chae SY; Son HJ; Lee DY; Shin E; Oh JS; Seo SY; Baek S; Kim JY; Na SJ; Moon DH
EJNMMI Res; 2020 May; 10(1):54. PubMed ID: 32448947
[TBL] [Abstract][Full Text] [Related]
8. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
9. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
10. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
13. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract][Full Text] [Related]
14. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
15. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer.
Yamane T; Ueda S; Seto A; Kuji I
Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433
[TBL] [Abstract][Full Text] [Related]
16.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
17. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
18.
Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
[TBL] [Abstract][Full Text] [Related]
19. Head-to-Head Comparison between
Piccardo A; Fiz F; Treglia G; Bottoni G; Trimboli P
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407526
[No Abstract] [Full Text] [Related]
20. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]